Tumour cell heterogeneity in triple-negative breast cancer cells affects response to cisplatin, but not doxorubicin

Tumour cell heterogeneity affects cisplatin but not doxorubicin cytotoxicity in two phenotypes of the triple -negative breast cancer (TNBC) cell line, MDA-MB-231. A mesenchymal MDA-MB-231 phenotype was three times less sensitive to cisplatin than an epithelial-type phenotype from the same cell line, which has important implications in the success of TNBC chemotherapies.

Automated summary

Tumour cell heterogeneity affects the cytotoxicity of cisplatin but not doxorubicin in two phenotypes of the triple-negative breast cancer cell line, MDA-MB-231. The mesenchymal phenotype showed three times less sensitivity to cisplatin compared to the epithelial-type phenotype, which has significant implications for the efficacy of TNBC chemotherapies.